The Gonorrhea drugs in development market research report provides comprehensive information on the therapeutics under development for Gonorrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Gonorrhea. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Gonorrhea and features dormant and discontinued products.

GlobalData tracks 15 drugs in development for Gonorrhea by 11 companies/universities/institutes. The top development phase for Gonorrhea is preclinical with 11 drugs in that stage. The Gonorrhea pipeline has 13 drugs in development by companies and two by universities/ institutes.

The key targets in the Gonorrhea pipeline products market include DNA Gyrase, DNA Topoisomerase IV, and Interleukin 12.

The key mechanisms of action in the Gonorrhea pipeline product include DNA Gyrase Inhibitor with two drugs in Phase III. The Gonorrhea pipeline products include six routes of administration with the top ROA being Oral and seven key molecule types in the Gonorrhea pipeline products market including Small Molecule, and Vaccine.

Gonorrhea overview

Gonorrhea is a sexually transmitted disease (STD) caused by Neisseria gonorrhoeae bacterium. It can infect both males and females. The bacteria target the cells of the mucous membranes, including surfaces of the urethra, vagina, cervix, and endometrium, the lining of the eyelid, the throat, and fallopian tubes. Symptoms include painful urination, pus-like discharge from penis, increased vaginal discharge, abdominal pain, and pelvic pain. Treatment includes antibiotics.

For a complete picture of Gonorrhea’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.